Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Objective Epstein–Barr virus (EBV) has for long been associated with systemic lupus erythematosus (SLE). In this study, we investigated the levels of latent and lytic antigen EBV-specific T-cells and ...

Objectives Evaluation of disease activity in systemic lupus erythematosus (SLE) nephritis is a challenge, and repeated renal biopsies are usually needed in order to confirm a suspicion of flare. In a ...

Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...

1 Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Dept. of Nephrology, Leiden University Medical Center, Leiden, The Netherlands 2 Dept. of Nephrology, ...

1 Dept. of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Center, Amsterdam, The ...

1 Dept. of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden 2 Dept. of Neuroradiology, Karolinska University ...

Objectives Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and/or obstetric ...

Objective The heterogeneity of systemic lupus erythematosus (SLE) poses a challenge in clinical care. Several treatment options are available, but data on immunomodulating drug survival in SLE is ...